Dr. Brian Solow, MD

NPI: 1689665036
Total Payments
$72,854
2024 Payments
$14,279
Companies
15
Transactions
55

Payment Breakdown by Category

Consulting$65,548 (90.0%)
Other$4,700 (6.5%)
Food & Beverage$1,400 (1.9%)
Travel$1,207 (1.7%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $65,548 18 90.0%
Honoraria $4,700 2 6.5%
Food and Beverage $1,400 25 1.9%
Travel and Lodging $1,207 10 1.7%

Top Paying Companies

Company Total Records Latest Year
GENZYME CORPORATION $22,356 17 $0 (2024)
SANOFI-AVENTIS U.S. LLC $20,064 1 $0 (2018)
Allergan, Inc. $13,197 13 $0 (2020)
Gilead Sciences, Inc. $4,300 3 $0 (2024)
Boehringer Ingelheim Pharmaceuticals, Inc. $4,172 3 $0 (2023)
Janssen Global Services, LLC $3,120 2 $0 (2022)
H. Lundbeck A S $2,500 1 $0 (2021)
Pharmacosmos Therapeutics Inc. $2,200 1 $0 (2021)
Otsuka America Pharmaceutical, Inc. $487.72 6 $0 (2017)
PFIZER INC. $215.38 1 $0 (2019)

Payment History by Year

Year Amount Transactions Top Company
2024 $14,279 7 GENZYME CORPORATION ($11,699)
2023 $5,363 5 Boehringer Ingelheim Pharmaceuticals, Inc. ($2,385)
2022 $4,800 3 Janssen Global Services, LLC ($3,120)
2021 $4,700 2 H. Lundbeck A S ($2,500)
2020 $5,225 1 Allergan, Inc. ($5,225)
2019 $7,815 2 Allergan Inc. ($7,600)
2018 $29,627 13 SANOFI-AVENTIS U.S. LLC ($20,064)
2017 $1,045 22 Otsuka America Pharmaceutical, Inc. ($487.72)

All Payment Transactions

55 individual payment records from CMS Open Payments — Page 1 of 3

Date Company Product Nature Form Amount Type
12/09/2024 Gilead Sciences, Inc. Biktarvy (Drug) Consulting Fee Cash or cash equivalent $2,580.00 General
Category: HIV
11/27/2024 GENZYME CORPORATION Consulting Fee Cash or cash equivalent $1,972.00 General
11/27/2024 GENZYME CORPORATION DUPIXENT (Biological) Consulting Fee Cash or cash equivalent $1,430.00 General
Category: Immunology
11/21/2024 GENZYME CORPORATION Consulting Fee Cash or cash equivalent $2,874.19 General
11/04/2024 GENZYME CORPORATION CEREZYME (Biological) Consulting Fee Cash or cash equivalent $1,972.00 General
Category: Genetic Disease
04/12/2024 GENZYME CORPORATION Consulting Fee Cash or cash equivalent $1,972.00 General
04/01/2024 GENZYME CORPORATION Consulting Fee Cash or cash equivalent $1,479.00 General
10/26/2023 GENZYME CORPORATION Consulting Fee Cash or cash equivalent $1,233.00 General
10/03/2023 Boehringer Ingelheim Pharmaceuticals, Inc. Consulting Fee Cash or cash equivalent $2,385.00 General
08/24/2023 Gilead Sciences, Inc. Consulting Fee Cash or cash equivalent $860.00 General
07/27/2023 Sage Therapeutics, Inc. ZULRESSO (Drug) Food and Beverage In-kind items and services $24.92 General
Category: PSYCHIATRY/PSYCHOLOGY
05/23/2023 Gilead Sciences, Inc. Consulting Fee Cash or cash equivalent $860.00 General
12/20/2022 Boehringer Ingelheim Pharmaceuticals, Inc. Consulting Fee Cash or cash equivalent $1,680.00 General
01/06/2022 Janssen Global Services, LLC Consulting Fee Cash or cash equivalent $2,340.00 General
01/06/2022 Janssen Global Services, LLC Consulting Fee Cash or cash equivalent $780.00 General
07/14/2021 Pharmacosmos Therapeutics Inc. Monoferric (Drug) Honoraria Cash or cash equivalent $2,200.00 General
Category: Hematology
01/22/2021 H. Lundbeck A S Honoraria Cash or cash equivalent $2,500.00 General
12/05/2020 Allergan, Inc. DURYSTA (Drug) Consulting Fee Cash or cash equivalent $5,225.00 General
Category: GLAUCOMA
07/16/2019 Allergan Inc. Consulting Fee Cash or cash equivalent $7,600.00 General
06/26/2019 PFIZER INC. Food and Beverage In-kind items and services $215.38 General
12/10/2018 GENZYME CORPORATION NO PRODUCT DISCUSSED (Drug) Travel and Lodging Cash or cash equivalent $343.35 General
12/10/2018 GENZYME CORPORATION NO PRODUCT DISCUSSED (Drug) Travel and Lodging Cash or cash equivalent $74.73 General
12/10/2018 GENZYME CORPORATION NO PRODUCT DISCUSSED (Drug) Travel and Lodging Cash or cash equivalent $11.08 General
10/29/2018 GENZYME CORPORATION LEMTRADA (Drug), AUBAGIO Food and Beverage In-kind items and services $64.73 General
Category: MULTIPLE SCLEROSIS
10/16/2018 Allergan Inc. Food and Beverage In-kind items and services $102.93 General

About Dr. Brian Solow, MD

Dr. Brian Solow, MD is a Family Medicine healthcare provider based in Irvine, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/03/2005. The National Provider Identifier (NPI) number assigned to this provider is 1689665036.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brian Solow, MD has received a total of $72,854 in payments from pharmaceutical and medical device companies, with $14,279 received in 2024. These payments were reported across 55 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($65,548).

Practice Information

  • Specialty Family Medicine
  • Location Irvine, CA
  • Active Since 11/03/2005
  • Last Updated 03/29/2022
  • Taxonomy Code 207Q00000X
  • Entity Type Individual
  • Practice Solo Practitioner
  • NPI Number 1689665036

Products in Payments

  • NO PRODUCT DISCUSSED (Drug) $29,423
  • DURYSTA (Drug) $5,225
  • Biktarvy (Drug) $2,580
  • Monoferric (Drug) $2,200
  • CEREZYME (Biological) $1,972
  • DUPIXENT (Biological) $1,430
  • PRADAXA (Drug) $107.15
  • ENTRESTO (Drug) $64.83
  • LEMTRADA (Drug) $64.73
  • Trintellix (Drug) $54.75
  • ZULRESSO (Drug) $24.92

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Family Medicine Doctors in Irvine